Under the deal, which follows on a previous collaboration between the companies entered in 2008, Kinaxo will apply its quantitative phosphoproteomics platform PhosphoScout to assist in drug development.
As part of the deal, Kinaxo will use its PhosphoScout phosphoproteomics technology to assess drugs under development at Takeda.
The acquisition of the chemical proteomics firm allows Evotec it "to take earlier educated decisions on drug efficacy, safety, and response in patients."
Kinaxo will use it mass spectrometry-based technologies to quantitatively analyze post-translational modifications in proteins on a proteome-wide scale.
Kinaxo will apply its technologies to deconvolute molecular targets of compounds on which the drug company is currently performing drug discovery work.
The Japanese drug firm will use Kinaxo's Cellular Target Profiling, KinAffinity, and PhosphoScout products.
Kinaxo’s phosphoproteomic tools will support targeted treatment development at Roche.
The German biotech plans to invest €3 million to €4 million in biomarker development over the next two years.
Christian Jurinke, Jeff Protentis, Jürgen Schumacher
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.